Shares of revenue are estimates for quarter ended 2026-03-31, not figures from a filing.
Established Pharmaceutical Products
Branded generic medicines sold outside the United States, including treatments for digestive conditions, women's health, heart and metabolic conditions, pain, and respiratory infections.
Diagnostic systems and tests
Laboratory instruments, test kits, and rapid tests used to help detect or monitor conditions such as infections, cancer, heart problems, and thyroid disorders.
Nutrition products
Infant formula, adult nutrition drinks and powders, and products used for feeding patients in healthcare institutions, including Similac, Ensure, and PediaSure.
Heart and other medical devices
Products include pacemakers, heart valves, devices used to treat narrowed blood vessels, and implanted devices for chronic pain or movement disorders.
FreeStyle Libre
A continuous glucose monitoring system with a sensor worn on the body to measure glucose levels for people with diabetes.
Cologuard
A stool-based test used to screen for colorectal cancer; Abbott discussed it on its earnings call as part of its cancer diagnostics business.
Abbott develops, makes, and sells healthcare products around the world. Its businesses include branded generic medicines sold outside the United States, diagnostic tests and equipment, nutrition products, and devices for heart conditions, diabetes, and other needs. Its buyers include healthcare providers, distributors, retailers, government agencies, and consumers.
Built from Abbott Laboratories’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
$109.38-1.0%Nov 11 close
Figures through September 30, 2026, from the 10-Q filed November 4, 2026
Abbott makes and sells medicines, diagnostic tests, nutrition products, and medical devices.
The themes Abbott Laboratories is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plc$130BA+
SYKStryker Corp.$121.3BA+
EWEdwards Lifesciences Corporation$60.8BA+
GEHCGE Healthcare Technologies Inc.$37.4BA
GKOSGlaukos Corp$14.6BARose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now AEWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
BIIBBiogen Inc.Oct 28, 2026BAGraded B, now AGrade B
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 40 quarters of Abbott Laboratories’s grade history. The other 38 go back to November 2016.
